Growth Metrics

ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2016 - 2022)

Historic Non-Current Deferred Tax Liability for ImmunityBio (IBRX) over the last 7 years, with Q2 2022 value amounting to $162000.0.

  • ImmunityBio's Non-Current Deferred Tax Liability fell 470.59% to $162000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $162000.0, marking a year-over-year decrease of 470.59%. This contributed to the annual value of $162000.0 for FY2021, which is 9665.15% down from last year.
  • Latest data reveals that ImmunityBio reported Non-Current Deferred Tax Liability of $162000.0 as of Q2 2022, which was down 470.59% from $162000.0 recorded in Q1 2022.
  • ImmunityBio's 5-year Non-Current Deferred Tax Liability high stood at $4.8 million for Q4 2020, and its period low was $122000.0 during Q3 2018.
  • For the 4-year period, ImmunityBio's Non-Current Deferred Tax Liability averaged around $658000.0, with its median value being $170000.0 (2021).
  • In the last 5 years, ImmunityBio's Non-Current Deferred Tax Liability plummeted by 9665.15% in 2021 and then plummeted by 470.59% in 2022.
  • Quarter analysis of 4 years shows ImmunityBio's Non-Current Deferred Tax Liability stood at $122000.0 in 2018, then soared by 3865.57% to $4.8 million in 2020, then tumbled by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
  • Its Non-Current Deferred Tax Liability was $162000.0 in Q2 2022, compared to $162000.0 in Q1 2022 and $162000.0 in Q4 2021.